JPWO2021153665A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021153665A5 JPWO2021153665A5 JP2021574104A JP2021574104A JPWO2021153665A5 JP WO2021153665 A5 JPWO2021153665 A5 JP WO2021153665A5 JP 2021574104 A JP2021574104 A JP 2021574104A JP 2021574104 A JP2021574104 A JP 2021574104A JP WO2021153665 A5 JPWO2021153665 A5 JP WO2021153665A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- thiazol
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001345 alkine derivatives Chemical class 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 229940079593 drug Drugs 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- -1 (4S,5R)-1-(7,8-dihydro-[1,4]dioxino[2',3':5,6]benzo[1,2-d]thiazol-2-yl)-4-methyl -5-(prop-1-yn-1-yl)imidazolidin-2-one Chemical compound 0.000 claims 3
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 claims 3
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 208000019664 bone resorption disease Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- ANAOTIUCCCNAFW-UHFFFAOYSA-N CC#CC(CNC1=O)N1C1=NC(C2=C(C=C3)OCC2)=C3S1 Chemical compound CC#CC(CNC1=O)N1C1=NC(C2=C(C=C3)OCC2)=C3S1 ANAOTIUCCCNAFW-UHFFFAOYSA-N 0.000 claims 2
- SULJERCUOUORNW-UHFFFAOYSA-N CC#CC(CNC1=O)N1C1=NC(C2=C(C=C3)OCCO2)=C3S1 Chemical compound CC#CC(CNC1=O)N1C1=NC(C2=C(C=C3)OCCO2)=C3S1 SULJERCUOUORNW-UHFFFAOYSA-N 0.000 claims 2
- DYMLPFTYPBQTNH-GXSJLCMTSA-N C[C@@H]([C@@H](C#CC)N1C2=NC(C3=C(C=C4)OCC3)=C4S2)NC1=O Chemical compound C[C@@H]([C@@H](C#CC)N1C2=NC(C3=C(C=C4)OCC3)=C4S2)NC1=O DYMLPFTYPBQTNH-GXSJLCMTSA-N 0.000 claims 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 201000006347 Intellectual Disability Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000036626 Mental retardation Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- BPEHSAJBRGILNA-MRVPVSSYSA-N [C@H]1(C#CC)N(C=2SC3=CC=C4OCOC4=C3N=2)C(=O)NC1 Chemical compound [C@H]1(C#CC)N(C=2SC3=CC=C4OCOC4=C3N=2)C(=O)NC1 BPEHSAJBRGILNA-MRVPVSSYSA-N 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 229940005524 anti-dementia drug Drugs 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 239000003200 antithyroid agent Substances 0.000 claims 2
- 229940043671 antithyroid preparations Drugs 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 239000004083 gastrointestinal agent Substances 0.000 claims 2
- 229940127227 gastrointestinal drug Drugs 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000003723 learning disability Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000005495 thyroid hormone Substances 0.000 claims 2
- 229940036555 thyroid hormone Drugs 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000002560 nitrile group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000002664 nootropic agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000000565 sulfonamide group Chemical group 0.000 claims 1
- 125000000101 thioether group Chemical group 0.000 claims 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020013536 | 2020-01-30 | ||
| PCT/JP2021/003026 WO2021153665A1 (ja) | 2020-01-30 | 2021-01-28 | 新規アルキン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021153665A1 JPWO2021153665A1 (https=) | 2021-08-05 |
| JPWO2021153665A5 true JPWO2021153665A5 (https=) | 2024-01-24 |
Family
ID=77079174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574104A Pending JPWO2021153665A1 (https=) | 2020-01-30 | 2021-01-28 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230138851A1 (https=) |
| JP (1) | JPWO2021153665A1 (https=) |
| TW (1) | TW202140469A (https=) |
| WO (1) | WO2021153665A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021343770A1 (en) * | 2020-09-18 | 2023-05-18 | Carna Biosciences, Inc. | Amine derivative |
| JPWO2023008470A1 (https=) * | 2021-07-28 | 2023-02-02 | ||
| WO2023008472A1 (ja) * | 2021-07-28 | 2023-02-02 | カルナバイオサイエンス株式会社 | 新規ベンゾチアゾール誘導体 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100010894A (ko) * | 2008-07-23 | 2010-02-02 | 가부시키가이샤 키노파마 | Ｄｙｒｋ를 저해하는 화합물을 함유하는 의약 조성물 |
| CN103797002B (zh) * | 2011-08-19 | 2017-02-22 | 迪亚克森海特公司 | Dyrk1抑制剂及其用途 |
| WO2014069434A1 (ja) * | 2012-10-30 | 2014-05-08 | カルナバイオサイエンス株式会社 | 新規チアゾリジノン誘導体 |
| JP2015107945A (ja) * | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| GB201617339D0 (en) * | 2016-10-12 | 2016-11-23 | Lytix Biopharma As | Therapeutic compounds |
-
2021
- 2021-01-28 JP JP2021574104A patent/JPWO2021153665A1/ja active Pending
- 2021-01-28 WO PCT/JP2021/003026 patent/WO2021153665A1/ja not_active Ceased
- 2021-01-28 US US17/795,728 patent/US20230138851A1/en not_active Abandoned
- 2021-01-29 TW TW110103557A patent/TW202140469A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021153665A5 (https=) | ||
| JP2022501338A5 (https=) | ||
| JP6585158B2 (ja) | ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体 | |
| JP2020512337A5 (https=) | ||
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| JP2010534647A5 (https=) | ||
| JP2020514316A5 (https=) | ||
| RS52274B2 (sr) | Jedinjenje diarilhidantoina | |
| JP2005538099A5 (https=) | ||
| JP2012530779A5 (https=) | ||
| JP2020502092A5 (https=) | ||
| UA114178C2 (uk) | Комбінація, що включає інгібітор cdk4/6 і інгібітор pi3k, для лікування раку | |
| JP2013536833A5 (https=) | ||
| FI3487505T3 (fi) | Diaminofenotiatsiinien antaminen ja annostus | |
| JP2015522018A5 (https=) | ||
| JPWO2020057511A5 (https=) | ||
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| US20180092916A1 (en) | Methods of treating disease-induced ataxia and non-ataxic imbalance | |
| JP2019516756A5 (https=) | ||
| JP2016525104A5 (https=) | ||
| PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
| DE602005018634D1 (de) | Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien | |
| JP2021514380A5 (ja) | 筋障害及び骨障害を処置するための化合物及び組成物 | |
| JP2021529168A5 (https=) | ||
| RU2008102155A (ru) | ЗАМЕЩЕННЫЕ 3-СУЛЬФОНИЛ-[1,2,3]ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, ЛЕКАРСТВЕННАЯ СУБСТАНЦИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |